Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308094 | 0.93 | GSK3A (0.51) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL21657296 | 0.93 | GSK3A (0.51) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL21657304 | 0.90 | GSK3A (0.52) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL23308123 | 0.90 | GSK3A (0.51) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL23308106 | 0.85 | GSK3A (0.52) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL21657298 | 0.83 | GSK3A (0.53) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL23308117 | 0.82 | GSK3A (0.57) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL21657303 | 0.82 | GSK3A (0.59) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL10304238 | 0.80 | GSK3A (0.45) | GSK3AGSK3B | |
| SCHEMBL10303474 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2021-04-29 | — | — | US | disclosed |
| WO-2020023813-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | PIR, PNPO, IDO1 | GSK3A 1593/4885GSK3B 901/4885FLT3 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.